FOLH1 and prostate carcinoma: PSA response was a significant predictor of PFS and OS, while prior treatment with177Lu-PSMA-617 was significantly associated with poorer PFS.77The bone is a common site of prostate cancer metastasis, and some patients may present with diffuse osseous metastasis in a superscan pattern.79Patients with superscan pattern of osseous metastases were excluded from the VISION trial due to the potential of bone marrow toxicity that the long range of beta particles emitted by177Lu may cause.